Expertise in
3
conditions

Tsutomu Iwasa

Ikoma, JP 
Expertise in
3
conditions
Ikoma, JP 

Overview

Tsutomu Iwasa practices practicing medicine in Ikoma, Japan.

Mr. Iwasa is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Febrile Neutropenia, Extramammary Paget Disease, and Lung Cancer.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Ikoma, 6300293, Japan
Other Locations
Osaka, Japan
Sakai, Japan
Sakai, 5918011, Japan
Sayama, Japan
Kowakae, 5778502, Japan
Tokyo, Japan
Osakasayam, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
View 1 Less Clinical Trial

53 Total Publications

Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
Journal: Breast cancer (Tokyo, Japan)
Published: September 06, 2026

Frequently Asked Questions about Tsutomu Iwasa

Is Tsutomu Iwasa a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Tsutomu Iwasa is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tsutomu Iwasa participate in research or clinical trials?

Yes. Tsutomu Iwasa has published 53 articles and abstracts on conditions like Breast Cancer. You can view a list of Tsutomu Iwasa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Iwasa's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile